1. Case-control study of acute renal failure in patients with cystic fibrosis in the UK
- Author
-
Alan R. Watson, Imti Choonara, Alan R. Smyth, Sarah Lewis, Jean McGaw, and Carol Bertenshaw
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Pancreatic disease ,Adolescent ,Cystic Fibrosis ,Cystic fibrosis ,Nephrotoxicity ,Risk Factors ,Internal medicine ,medicine ,Tobramycin ,Humans ,Risk factor ,Child ,Infusions, Intravenous ,business.industry ,Aminoglycoside ,Case-control study ,Infant ,Acute Kidney Injury ,medicine.disease ,Surgery ,Anti-Bacterial Agents ,Aminoglycosides ,Case-Control Studies ,Child, Preschool ,Female ,business ,Kidney disease ,medicine.drug - Abstract
Background:There has been a recent increase in the number of reported cases of acute renal failure (ARF) in cystic fibrosis (CF). A case-control study was conducted to determine the factors which are associated with an increased risk of ARF.Methods:24 cases of confirmed ARF were identified in patients with CF from 20 UK CF centres presenting between 1997 and 2004. Using the UK CF database, sex- and age-matched controls were identified. Risk factors were analysed by conditional logistic regression and Mantel-Haenszel analysis.Results:21 of the 24 patients with ARF had received an aminoglycoside at the time of their episode of ARF or in the preceding week compared with only 3 of 42 controls during the same time period (OR 81.8, 95% CI 4.7 to 1427, pConclusions:In patients with CF the use of an intravenous aminoglycoside is a risk factor for ARF; gentamicin is more nephrotoxic than tobramycin. Most patients who develop ARF have a risk factor which necessitates withholding aminoglycosides or more closely monitoring their use.
- Published
- 2008